Keresés eredménye

Típusa:

összetett keresés

Keresési paraméterek:

Cyrille Hulin, MD | szakcikk |

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!

1875 Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of MaiaClinically Relevant Abstract

Szerző: Nizar Bahlis, MD¹ Thierry Facon, MD² Saad Z. Usmani, MD³ Shaji K. Kumar, MD⁴ Torben Plesner, MD, DSc⁵ Robert Z. Orlowski, MD, PhD⁶ Cyrille Touzeau, MD⁷ Supratik Basu, MBBS, MD, FRCP, FRCPath⁸ Hareth Nahi, MD, PhD⁹ Cyrille Hulin, MD¹⁰ Hang Quach, MD¹¹ Hartmut Goldschmidt¹² Michael E O'Dwyer, MD¹³ Christopher P Venner, MD¹⁴ Katja C. Weisel, MD¹⁵ Maria Krevvata, PhD¹⁶ Huiling Pei, PhD¹⁷ Jianping Wang¹⁸ Rian Van Rampelbergh¹⁹ Jon Ukropec, PhD²⁰ Clarissa M. Uhlar²¹ Rachel Kobos, MD²² Aurore Perrot²³
¹University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, AB, Canada
²Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France
³Levine Cancer Institute/Atrium Health, Charlotte, NC
⁴Division of Hematology, Mayo Clinic, Rochester, MN
⁵Vejle Hospital and University of Southern Denmark, Vejle, Denmark
⁶Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Hematology, University Hospital Hôtel-Dieu, Nantes, France
⁸Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom
⁹Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden
¹⁰Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France
¹¹St. Vincent's Hospital, Melbourne, Australia
¹²University Hospital Heidelberg and National Center of Tumor Diseases (NCT), Heidelberg, Germany
¹³Dept. of Medicine/Haematology, NUI, Galway, Ireland
¹⁴Division of Medical Oncology, University of Alberta, Edmonton, AB, Canada
¹⁵Medical Center of Hamburg-Eppendorf, Hamburg, Germany; University of Tuebingen, Tuebingen, Germany
¹⁶Janssen Research & Development, LLC, Spring House, PA
¹⁷Janssen Research & Development, LLC, Titusville, NJ
¹⁸Janssen Research & Development, LLC, Raritan, NJ
¹⁹Janssen Research & Development, Beerse, Belgium
²⁰Janssen Global Medical Affairs, Horsham, PA
²¹Janssen Research & Development, LLC, Spring House, PA
²²Janssen Research & Development, LLC, Raritan, NJ
²³Hematology Department, University Hospital, Vandoeuvre Les Nancy, France

Conclusion: After longer follow up, the addition of DARA to Rd continues to demonstrate a significant PFS benefit and improved rates of deeper and more durable responses vs Rd alone in patients with transplant-ineligible NDMM. The longer follow-up also demonstrated a significant improvement in PFS2 favoring D-Rd, and no new safety concerns were observed. These results continue to support the use of D-Rd in the first line of treatment for ...

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!